NAD+

NAD+ (nicotinamide adenine dinucleotide) is a fundamental cofactor involved in cellular energy metabolism, redox reactions, and numerous signaling pathways. Interest in NAD+ has expanded beyond basic biochemistry into discussions of aging, mitochondrial function, and metabolic health.

The NAD+ pool in the body can be influenced by dietary precursors, endogenous synthesis, and certain interventions that aim to support or modulate cellular metabolism.

NAD+ participates in a wide range of cellular processes. At a high level, it:

• Serves as an electron carrier in mitochondrial energy production
• Acts as a substrate for enzymes such as sirtuins and PARPs
• Influences redox balance and cellular stress responses

Because of this central role, changes in NAD+ availability have been linked, in research settings, to metabolic resilience, aging-related processes, and response to cellular stress.

In regulated medicine, NAD+ and related formulations may be used in specific clinical contexts defined by local standards, such as certain deficiency states or alongside established therapies. In parallel, there is a growing ecosystem of wellness and longevity offerings that reference NAD+ biology.

The regulatory status, labeled indications, and quality standards around NAD+ products vary substantially by jurisdiction and product type (e.g., oral supplements, intravenous preparations). This page focuses on general concepts rather than endorsing any particular application.

Reported effects associated with NAD+-related interventions have included flushing, gastrointestinal upset, and transient changes in energy or sleep patterns. Intravenous preparations may carry additional procedure-related considerations.

As with any intervention, individualized risk–benefit assessment and attention to product quality and regulatory guidance are essential.

NAD+ administration varies widely between clinical IV drips and home subcutaneous protocols.

This information summarizes commonly discussed practices. NAD+ is known for individual sensitivity; lower starting doses are often recommended.

Three distinct product categories are sold under one banner, and their evidence bases do not transfer between them:

• Oral precursors — nicotinamide riboside and nicotinamide mononucleotide, which cells convert into NAD+. This is where nearly all randomized human data sit, including the 1,000 mg/day NR crossover trial (PMID 29599478).
• Injectable NAD+ — supplied as powder for reconstitution, with no controlled trial establishing an amount.
• Intravenous NAD+ — the most heavily marketed form and the least studied. The one published human protocol was a 6-hour infusion at 3 µmol/min run purely to characterize disposition (PMID 31572171).

Combination "drips" pairing NAD+ with vitamins or other agents add further variables without adding trial evidence for the combination.

Research on NAD+ spans basic biochemistry, animal models of aging and metabolism, and emerging human studies. Topics of interest include metabolic flexibility, neurodegenerative processes, and markers of cellular stress.

While enthusiasm is high, much work remains to define which populations, formulations, and dosing strategies—if any—translate into clear clinical benefits. Careful reading of the primary literature is important to separate early signals from established evidence.

For deeper dives on this peptide, see:

• NAD+ benefits and areas of interest
• NAD+ side effects and safety context
• NAD+ dosing concepts (educational)
• NAD+ research and evidence overview

Does the human evidence support IV NAD+? No. The randomized human trials in this space tested oral precursors, not intravenous NAD+. The only published human IV protocol was a pharmacokinetic pilot — a 6-hour infusion at 3 µmol/min — run because, as its authors noted, no data existed on the fate of directly infused NAD+ in people (PMID 31572171). It measured where the molecule went, not whether it helped.

Does supplementation actually raise NAD+? Yes. In a 2×6-week randomized, double-blind, placebo-controlled crossover trial, 1,000 mg/day of nicotinamide riboside raised NAD+ in peripheral blood mononuclear cells by roughly 60% versus placebo and was well tolerated with no serious adverse events (Martens et al., Nature Communications, 2018).

Did raising it produce a benefit? Not in the trials that looked for one. The Nature Reviews Molecular Cell Biology review of the field summarizes NR studies in overweight and obese adults directly: NAD+ levels rose, but participants "showed no signs of weight loss, increased insulin sensitivity or enhanced mitochondrial function" (Covarrubias et al., 2021). In the Martens trial the blood-pressure and arterial-stiffness signals did not survive correction for multiple comparisons.

Is NAD+ a peptide? No. It is a dinucleotide coenzyme, sold alongside peptides but chemically unrelated to them.

Is any of it FDA-approved? No. NAD+ and NMN are not approved drugs for any indication; NMN's dietary-supplement status in the United States has been contested because it was investigated as a drug, and NAD+ appears on FDA lists of substances raising concerns for compounding.